摘要
1990年我们曾经报道卡铂的Ⅱ期临床试验结果。自199i年10月至1992年10月,卡铂临床协作组共十二间医院继续应用德州制药厂生产的卡铂单药治疗或联合其它抗癌药物治疗各类恶性肿瘤共529例,单药治疗总有效率26.5％,联合化疗总有效率_45％,主要毒性反应为轻度或中度的骨髓抑制和胃肠道反应,患者一般均可耐受。本组治疗结果再次表明卡铂是一种有效低毒广谱的新抗癌药。
We have demonstrated the anti-cancer effect of Carboplatin in thephase II clinical trial in 1990. From October 1991 to October 1992, 529 cases of various malignancies were treated with carboplatin (made in Dezhou) by the Carboplatin Cooperating Study Group either alone or in combination with other cytostatics. The overall responce rates for carboplatin alone and carboplatin-containing regimans were 26.5% and 45% respectiv-vely. The main toxicities and side effects were myelosuppression and gastrointestinal tract reaction, in most cases were grade 1-11 and well tolerated. Our study revealed again that carboplatin was an effective broad-spectrum and well tolerated anticincer drug.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
1993年第3期223-226,共4页
Chinese Journal of Cancer
